Among active 13F managers last quarter, 1 opened and 1 reduced; the largest holder to move was Warberg Asset Management LLC (−0.3%). No recent Form 4 insider filings for NXGLW.
No leg leans either way.
5 tracked 13F filers disclose a position in NXGLW as of the latest SEC 13F filings, a combined $41K in reported value. Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| # | Fund | Shares | Position value | Last move | As of | History |
|---|---|---|---|---|---|---|
| 1 | Armistice Capital, LLC | 550K | $33K | —Held | Q1 2026 | |
| 2 | Warberg Asset Management LLC | 146K | $5K | ▼−0.3% Reduced · −500 sh | Q2 2026 | |
| 3 | Clear Street Group Inc. | 51K | $2K | ▲+0.4% Added · +200 sh | Q2 2026 | |
| 4 | Two Sigma Securities, LLC | 22K | $584 | ▲New +22K sh | Q2 2026 | |
| 5 | UBS Group AG | 16K | $724 | ▲13× Added · +15K sh | Q1 2026 |
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
Last quarter, 1 fund opened a new position in NXGLW, while 1 reduced. Based on 13F filings from active, signal-eligible managers (passive index funds and other mechanical holders are excluded from this count).
| Company | Co-held by | Their position there |
|---|---|---|
| Biovie Inc -30BIVIW | 3 funds | $437K |
| PTC Therapeutics IncPTCT | 2 funds | $141.6M |
| Madrigal Pharmaceuticals IncMDGL | 2 funds | $139.7M |
| Incyte CorpINCY | 2 funds | $62.1M |
| Dyne Therapeutics IncDYN | 2 funds | $57.8M |
| Ironwood Pharmaceuticals IncIRWD | 2 funds | $52.8M |
| Uber Technologies IncUBER | 2 funds | $38.8M |
| Alphabet Inc-CL AGOOGL | 2 funds | $34.8M |
| Hubspot IncHUBS | 2 funds | $31.6M |
| Regeneron PharmaceuticalsREGN | 2 funds | $31.5M |
| Avanos Medical IncAVNS | 2 funds | $28.3M |
| Mongodb IncMDB | 2 funds | $27.8M |
Ranked by how many of NXGLW's tracked holders also hold each name. The last column is those co-holders' combined reported position in that name, not in NXGLW.
No open-market insider transactions on file yet. Grants, gifts, and exercises live on the full insider page.
Where institutional funds (13F), corporate insiders (Form 4) and US House members (STOCK Act) are buying or selling the same name in the same window. Green is buying, red is selling.
Insiders and Congress: last 180 days. Funds: latest 13F, top 100 holders incl. passive
| Source | Buying | Selling | Net |
|---|---|---|---|
13F funds Top 100 holders by value, passive included; the hero counts active managers only | 2 | 1 | – |
Insiders Form 4 open-market | 0 | 0 | $0 |
US House STOCK Act trades | 0 | 0 | $0 |
Capital Rotation reports where institutional capital disclosed rotating, as of the latest public SEC 13F filings. It is data, not investment advice, a recommendation, or a prediction. Filings lag about 45 days and cover long US equity positions only. Past disclosed flows do not indicate future prices. Do your own research; consult a licensed advisor.
No filings captured for this ticker in the live stream yet.
Connected entities for NXGLW
This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/NXGLW/capital-change-brief"
Use Arkolith's capital_change_brief for NXGLW. Tell me what changed, whether insider activity corroborates it, and cite the SEC evidence.
13F holdings + Form 4 insider transactions + the live filing stream, joined for NXGLW. Filings are public domain, sourced to SEC EDGAR.